TYRA Tyra Biosciences, Inc.
$20.42▼ -0.15%
Healthcare
Other
Volume 789.8K
Avg Volume (10D) 636.1K
Key Metrics & Fundamentals
Market Cap
$1.40B
P/E Ratio
–
Div Yield
0.00%
52W Range
13.35 - 40.65
% vs 50 MA
-11.42%
% vs 200 MA
-31.99%
RSI-14
45.1
MACD Histogram
+0.3300
Beta (1Y vs SPY)
0.40
Free Cash Flow
-$31.14M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$48.87M
COGS
–
Operating Exp
$49.00M
Operating Income
-$49.00M
EBIT
-$49.00M
Pretax Income
-$45.56M
Net Income
-$45.56M
EPS (Diluted)
-0.69
Price & Volume History
Loading chart…
Recent News
Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value
Simply Wall St. · Oct 17, 2026 3:11 AM ET
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks
Zacks · Oct 14, 2026 8:35 AM ET
Raymond James Updates Healthcare Top Picks for October
Investing.com · Oct 1, 2026 4:26 PM ET
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?
Insider Monkey · Sep 16, 2026 4:07 PM ET
Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets
Simply Wall St. · Sep 16, 2026 11:13 AM ET
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PR Newswire · Sep 14, 2026 6:45 AM ET
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
Investor's Business Daily · Sep 9, 2026 4:54 PM ET
Tyra disappoints investors with bladder cancer data
BioPharma Dive · Sep 9, 2026 11:46 AM ET
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Barrons.com · Sep 9, 2026 10:44 AM ET
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
InvestorsHub · Sep 9, 2026 10:05 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See TYRA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.